Cancer Institute Of The Good Samaritan Hospital - Los Angeles, California 90017

Cancer Institute Of The Good Samaritan Hospital is categorized under Noncommercial Research Organizations in Los Angeles, CA .

Business Name: Cancer Institute Of The Good Samaritan Hospital
Contact Person: Alan M Ino
Address: 616 Witmer St, Los Angeles, California 90017
Phone Number: (213) 977-2121
Annual Revenue (USD): $0 to $49.999
Founding Year: 2011
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Noncommercial Research Organizations
SIC Code: 8733
NAICS Code: 541720
Share This Business:
Related Businesses: Heart Institute Of The Good Samaritan Hospital - Los Angeles, CA 90017
Courage Campaign Issues - Los Angeles, CA 90017
Innovative Hybrid Technologies - Los Angeles, CA 90017
American Institute of Research - Los Angeles, CA 90017
The Institute For Reproductive Research Of The Hospital Of The Good Samaritan - Los Angeles, CA 90017
Los Angeles Thoracic Cardio - Los Angeles, CA 90017
Jetro-Los Angeles - Los Angeles, CA 90017
Pacific Institute Inc - Los Angeles, CA 90017
Sylvatex Biofuels LLC - Los Angeles, CA 90017

The company Cancer Institute Of The Good Samaritan Hospital provides B2B services in the form of Noncommercial Research Organizations from its single location in California. 1 to 4 employees work for Cancer Institute Of The Good Samaritan Hospital, and the business now earns $0 to $49.999 per annum.

Cancer Institute Of The Good Samaritan Hospital was launched in 2011 and is classified under SIC code and category 8733 , and NAICS number and grouping 541720 . To contact Cancer Institute Of The Good Samaritan Hospital, please call Alan M Ino with the phone number (213) 977-2121 or visit its single location at 616 Witmer St in Los Angeles, California 90017.

The location of the single location can also be found using the coordinates 34.054681,-118.26591. Read more details about this business on the webpage or follow the company’s social media accounts, on Twitter and on Facebook.